levetiracetam / Generic mfg. - LARVOL DELTA

Levetiracetam in critically ill patients with augmented renal clearance: a systematic review. (PubMed, Eur J Clin Pharmacol) - No abstract available

Journal • Review • Critical care

NEURONAL DNA DAMAGE AND HYPERACTIVITY DRIVE T CELL-NEURON INTERACTIONS IN ALZHEIMER (ADPD 2026) - "These findings suggest that T cell infiltration into the brain parenchyma and T cell-neuron interactions are governed by neuronal DNA damage and neuronal hyperactivity."

Alzheimer's Disease • CNS Disorders • CD8

Characteristics associated with first anti-seizure medication prescribed in a cohort of adults with newly diagnosed epilepsy. (PubMed, Seizure) - "Understanding where/why less favorable ASM prescription may occur is important to target potential prescribing interventions. In this study, recommended ASM prescriptions were associated with patient, prescriber and setting characteristics. Notably, trainees prescribed recommended/neutral ASM more often, which underscores the importance of prescriber education in improving prescribing practices."

Journal • Cardiovascular • CNS Disorders • Epilepsy

BIN1 DRIVES AD-LIKE NEURONAL HYPEREXCITABILITY BY ELIMINATING INHIBITORY SYNAPSES (ADPD 2026) - "There is clear translational potential: hyperexcitability caused by BIN1 deficiency can be rescued by levetiracetam, an antiepileptic drug already in clinical use. Bin1 is an inhibitory presynaptic protein whose function is affected by LOAD mutations. Bin1 is an inhibitory presynaptic protein whose function is affected by LOAD mutations. Loss of Bin1 function eliminates inhibitory synapses and may lead to hyperexcitability, thereby accelerating the loss of excitatory synapses. This study shows that BIN1 is the first protein associated with Alzheimer's disease linked to inhibitory synapses and neuronal hyperexcitability, revealing a mechanism that operates upstream of Aβ accumulation."

Alzheimer's Disease • CNS Disorders

ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study. (PubMed, Haematologica) - "With Axicabtagene-ciloleucel and Brexucabtagene-autoleucel, overall and severe ICANS reach 78% and 35%, respectively...The protocol included levetiracetam and thiamine prophylaxis, early grade-based corticosteroids and anakinra for grade ≥3 and refractory ICANS - defined as no improvement within 24hr...mEASIX and ICANS-PSS scores were not predictive; expansion was not compromised. Cumulative steroids associated with infections (p=.002) and NRM (p."

Journal • Infectious Disease

Interictal focal epileptic discharges in a pediatric patient with absence status epilepsy: a mimicker of focal epilepsy. (PubMed, Epilepsy Behav Rep) - "At age seven, ictal EEG revealed almost continuous, irregular generalized SW and PSW discharges with maximal amplitude over the frontal regions...Despite initial treatment with levetiracetam and clobazam, absence status epilepticus recurred when continuous intravenous midazolam was discontinued...Diagnosing absence seizures in ASE is further complicated by their prolonged duration, which makes onset and termination difficult to document. Valproic acid was effective for long-term seizure control, whereas intravenous benzodiazepines achieved rapid seizure suppression."

Journal • Absence Seizure Disorder • CNS Disorders • Epilepsy • Pediatrics

Trends in paediatric antiseizure-medication use and costs in France, 2014-2023: a nationwide population-based analysis. (PubMed, Lancet Reg Health Eur) - "Prescriptions by private psychiatrists and use of gabapentin, pregabalin, lamotrigine, and levetiracetam independently predicted generic uptake. Targeted substitution strategies could release funds for innovative therapies without compromising seizure control. None."

Journal • CNS Disorders • Epilepsy • Pediatrics • Psychiatry

KCNT1-related epilepsy presenting with severe polyhydramnios (ACMG 2026) - "Outcome and Follow-Up The infant had APGARS of 5 and 9, and a 49-day course in the NICU with management by neurology for refractory seizures requiring multiple antiepileptic drugs, including a combination of levetiracetam, clobazam, and cannabidiol. Our case demonstrates that isolated severe polyhydramnios may be a sign of an underlying fetal genetic syndrome with a severe neurologic phenotype and warrants consideration of molecular genetic testing with prenatal exome or genome sequencing. Conclusion Isolated severe polyhydramnios on prenatal ultrasound may be a sign of an underlying fetal genetic syndrome with a severe neurologic phenotype and should prompt consideration of molecular genetic testing with prenatal exome or genome sequencing."

Cardiovascular • CNS Disorders • Developmental Disorders • Epilepsy • Gene Therapies • Mental Retardation • Movement Disorders • Pulmonary Disease

Combined oxidative phosphorylation deficiency 35 due to TRIT1 variants: Novel phenotypes and ketogenic diet utilization (ACMG 2026) - "Current antiseizure and adjunctive medications include Onfi, Vimpat, leucovorin, Keppra, levocarnitine, and vigabatrin. Finally, progressive cerebral and cerebellar atrophy were demonstrated on repeat brain MRI, which has not previously been reported and may indicate utility of repeated brain imaging throughout disease course. Conclusion We describe a case of COXPD35 that increases the limited clinical understanding of disease spectrum, cardiac and brain abnormality phenotypes, and ketogenic diet for management of epileptic encephalopathy."

Cardiomyopathy • Cardiovascular • CNS Disorders • Developmental Disorders • Dystonia • Epilepsy • Mental Retardation • Movement Disorders • Ocular Inflammation • Ophthalmology • Rare Diseases • Strabismus • BCL11B

When speed matters: ultra-rapid genome diagnosis enables precision therapy in FGF12-related developmental and epileptic encephalopathy (ACMG 2026) - "Diagnostic Workup Despite treatment with levetiracetam, phenobarbital, midazolam, and a medically induced coma with ketamine, his seizures persisted...At present, his medications include levetiracetam, oxcarbazepine, lacosamide, and pantoprazole...This case expands the phenotypic spectrum of DEE47, particularly the possibility of respiratory complications, and further demonstrates the potential for urGS to rapidly identify actionable molecular diagnoses in critically ill infants. Conclusion This case expands the phenotypic spectrum of DEE47, particularly the possibility of respiratory complications, and highlights the utility of ultra-rapid genome sequencing in guiding timely diagnosis and precision treatments in epilepsy."

CNS Disorders • Developmental Disorders • Epilepsy

Mosaic FBXW7-related Neurodevelopmental Disorder Presenting with Developmental Delay, Hypotonia, Expressive Language Delay, Anorectal Malformation, and Proximal Aorta Dilation (ACMG 2026) - "She started levetiracetam following abnormal EEG with improvement in abnormal spells and epileptiform discharges...This variant has been previously identified in cancers but not as causing neurodevelopmental disorder. This case expands the phenotypic spectrum of this recently described rare condition, including anorectal malformation and aortic dilation not previously reported."

Neurodevelopmental • Autism Spectrum Disorder • CNS Disorders • Constipation • Developmental Disorders • Endometrial Cancer • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Heart Failure • Mental Retardation • Nephrology • Psychiatry • Renal Calculi • Solid Tumor • Targeted Protein Degradation • Wilms Tumor • FBXW7 • PCM1

Presentation of an individual with a 3.3 Mb duplication in 3q13.2q13.31 (ACMG 2026) - "He had moderate intellectual disability and epilepsy, for which he was taking a pediatric dose of carbamazepine with decreasing efficacy...At age 26, his epilepsy medication was switched to levetiracetam 2000 mg/day with breakthrough seizures, and increased to 3000 mg/day after three weeks. His epilepsy remains uncontrolled and sodium valproate is being considered...Conclusion The individual we present expands the phenotype of the (3q13.2q13.31) duplication syndrome, and the creatine findings we describe suggests a possible metabolic component to this condition. Future considerations include a brain MRI and repeat ES since the initial genomic investigation was done in 2017."

Clinical • CNS Disorders • Developmental Disorders • Epilepsy • Genetic Disorders • Mental Retardation

High- and Low-Grade Gliomas Identified in Two Pediatric Patients with Germline PALB2 Variants (ACMG 2026) - "Currently, Patient A is on cycle 3 of ONC028 following discontinuation of adjuvant chemotherapy due to disease progression and obstructive hydrocephalus, focal re-irradiation, and intolerance to everolimus and trametinib...Following resection, Patient B continued on levetiracetam and was seizure-free for nearly 3 months but was transitioned to oxcarbazepine due to intolerable side effects. Thirteen months post-surgery, there is no evidence of tumor recurrence, although he continues to experience intermittent seizures. Conclusion Further studies are needed to assess whether pathogenic variants in PALB2 may increase risk for glioma in pediatric patients."

Clinical • Brain Cancer • Breast Cancer • CNS Disorders • Diffuse Midline Glioma • Epilepsy • Ganglioglioma • Glioma • High Grade Glioma • Hypotension • Medulloblastoma • Ovarian Cancer • Pediatrics • Solid Tumor • Ventriculomegaly • BRCA2 • FGFR2 • H3-3A • NF1 • PALB2 • PDGFRA • TP53

Impact of Specialty Clinic Evaluation on Antiepileptic Prescribing Patterns in Patients with Angelman Syndrome (ACMG 2026) - "While there are no universally accepted guidelines for the pharmacologic management of epilepsy in Angelman syndrome, the literature increasingly recommends newer antiepileptic agents such as levetiracetam, lamotrigine, and clobazam as first-line agents in Angelman syndrome given their similar efficacy and more favorable side effect profile when compared to older antiepileptic medications such as valproate. This study demonstrates that engagement with the University of North Carolina Angelman Syndrome Clinic is associated with improved adherence to current recommendations for the pharmacologic management of epilepsy in Angelman syndrome. These findings highlight the value of multidisciplinary specialty clinic involvement in optimizing pharmacologic treatment plans and potentially improving overall clinical outcomes in patients with Angelman syndrome."

Clinical • CNS Disorders • Epilepsy

Reclassification of a Cerebral Palsy Diagnosis: Adult Presentation of Angelman Syndrome due to Paternal Uniparental Disomy (ACMG 2026) - "Treatment and Management Seizures were managed with levetiracetam, and supportive care addressed gait instability and sleep disturbance...This case demonstrates how a long-standing CP diagnosis was reclassified as Angelman syndrome due to paternal UPD, reinforcing both the clinical and ethical imperative for genetic evaluation. Broader adoption of genetic testing guidelines in CP may shorten the diagnostic odyssey, prevent misclassification, and improve long-term outcomes for patients and families."

Clinical • Cerebral Palsy • CNS Disorders • Developmental Disorders • Epilepsy • Fragile X Syndrome • Genetic Disorders • Mental Retardation • Sleep Disorder • UBE3A

Intermediate Form of Menkes in an African American Individual: A Case Report (ACMG 2026) - "The ATP7A variant was subsequently reclassified by the testing laboratory to likely pathogenic following negative testing for patient's biological mother and twin brother Treatment and Management His first seizure was at 2.5 years old (febrile) and Keppra and Vimpat were started. Conclusion We present the case of a patient with a more intermediate form of Menkes disease, who displayed nonspecific findings in infancy prior to diagnosis at age ~2.5 years. Our case underscores the importance of characterizing this area of the disease spectrum to improve patient outcomes."

Case report • Clinical • CNS Disorders • Developmental Disorders • Dystonia • Epilepsy • Infectious Disease • Movement Disorders • ATP7A • B2M

Homozygous 6p deletion results in significant seizures, hypotonia, and global developmental delay. (ACMG 2026) - "Keppra was started and initially stopped the seizures...Outcome and Follow-Up The patient's seizures are well managed on phenobarbital; he has been seizure free for 6 months...Conclusion Homozygous deletion of 6p including part of the GABBR1 gene, results in phenotype characterized by significant seizures, hypotonia, and global developmental delay. While heterozygous de novo loss of function variants in GABBR1 are well-described in literature, this deletion is expected to result in biallelic loss of function in this gene resulting in intractable seizures and profound developmental delays."

Clinical • Cardiovascular • CNS Disorders • Cognitive Disorders • Developmental Disorders • Epilepsy • Gastroesophageal Reflux Disease • Hematological Disorders • Hypertension • Mental Retardation

Response to bilateral globus pallidus interna (GPi) deep brain stimulation in a woman with dystonia due to ATP1A3 p.Arg756Cys (ACMG 2026) - "Her epilepsy is responsive to levetiracetam monotherapy...Treatment and Management After earlier treatment with botulinum toxin and baclofen and unsuccessful trials of carbidopa-levodopa, the patient underwent bilateral GPi DBS placement at age 17...She remains on clonazepam, which has shown efficacy for her dystonia...Conclusion Genotype-phenotype correlation for DBS responsiveness and effect of disease duration prior to DBS placement remain unknown. These issues of patient and target selection are worthy of further study."

Clinical • Ataxia • CNS Disorders • Depression • Dystonia • Epilepsy • Infectious Disease • Movement Disorders • Parkinson's Disease • Postpartum Depression

Multigenerational Presentation of MARK2-Related Disorders (ACMG 2026) - "After seizure like activity was noted, an EEG was performed and abnormal leading his neurologist to prescribe him oxcarbazepine at 12 years old...The female twin also has a diagnosis of epilepsy and is prescribed levetiracetam...Our affected patients' phenotypes exclusively overlap with the previously described phenotype offering further support to this newly described genetic neurodevelopmental disorder. Conclusion Given the small number of cases reported in the literature thus far, the additional clinical information that this family can add to the medical literature is impactful."

ADHD (Impulsive Aggression) • Astigmatism • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Epilepsy • Genetic Disorders • Mental Retardation • Mood Disorders • MARK2

A 62-Year-Old-Man With Severe Daytime Sleepiness After Primary Central Nervous System Lymphoma. (PubMed, Chest) - "Remission was achieved after a course of high-dose methotrexate, rituximab, and whole-brain radiotherapy...He had no dyspnea, cough, or history of aspiration pneumonia. Medications included levetiracetam and midodrine."

Journal • B Cell Lymphoma • CNS Lymphoma • Cough • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Primary Central Nervous System Lymphoma • Pulmonary Disease • Respiratory Diseases

Reply to comment on "Seizure and behavioral outcomes after switching from levetiracetam to brivaracetam in pediatric epilepsy: A real-world cohort study and literature review". (PubMed, J Formos Med Assoc) - No abstract available

Journal • Real-world evidence • CNS Disorders • Epilepsy • Pediatrics

Levetiracetam prevents Aβ production through SV2a-dependent modulation of APP processing in Alzheimer's disease models. (PubMed, Sci Transl Med) - "Last, early Aβ pathology in brains from donors with Down syndrome was characterized by elevated presynaptic proteins. Together, these findings highlight the potential to prevent Aβ pathology before irreversible damage occurs."

Journal • Alzheimer's Disease • CNS Disorders • Developmental Disorders • Genetic Disorders • APP • Aβ42

Analysis of ASMs and male infertility using the FDA adverse event reporting system (FAERS). (PubMed, Front Public Health) - "Disproportionality analysis revealed that carbamazepine (ROR = 8.73; IC = 3.10) and valproic acid (ROR = 6.82; IC = 2.74) posed the highest risks. Oxcarbazepine, lamotrigine, and levetiracetam also showed positive signals. Phenytoin sodium, topiramate, and clonazepam showed no significant risk...Despite the limitations of the FAERS database, these findings emphasize the importance of monitoring reproductive health in male patients, particularly those of childbearing age, and highlight the need to balance ASM efficacy with potential reproductive toxicity in clinical practice. Further research is needed to validate these findings and explore underlying mechanisms."

Adverse events • Journal • CNS Disorders • Epilepsy • Infertility • Sexual Disorders

Brivaracetam Use in Managing Seizures Following Traumatic Brain Injury. (PubMed, Cureus) - "BRV and LEV demonstrated comparable efficacy in preventing post-traumatic seizures in TBI patients. However, seizure incidence did not differ significantly in this sample. Although the study was underpowered for this outcome, BRV was associated with superior neurobehavioral outcomes, particularly during the early recovery period. These findings suggest that BRV may offer a more favorable tolerability profile for seizure prophylaxis following TBI. Larger multicenter studies are warranted to validate these results."

Journal • CNS Disorders • Epilepsy • Vascular Neurology

THE COST OF LOST FOLLOW-UP: A DIAGNOSIS OF SARCOMATOID LUNG CARCINOMA FOLLOWING A PRESUMED BENIGN PULMONARY MASS AND THE NECESSITY OF PHYSICIAN SUSPICION (WRMC 2026) - "He was treated with dexamethasone and levetiracetam. Picture 1. Initial CT chest with contrast coronal view shows a large right upper lobe mass measuring 8x6x7 cm."

CNS Disorders • Epilepsy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Sarcoma • Solid Tumor